Briacell TherapeuticsBCTX
Market Cap: $13.3M
About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Employees: 12
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
342% more call options, than puts
Call options by funds: $137K | Put options by funds: $31K
0% more funds holding
Funds holding: 20 [Q1] → 20 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
11.74% less ownership
Funds ownership: 13.88% [Q1] → 2.14% (-11.74%) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
93% less capital invested
Capital invested by funds: $6.45M [Q1] → $459K (-$5.99M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for BCTX.